MihÃily Balogh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8758534/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine. Antioxidants and Redox Signaling, 2022, 36, 122-143.	5.4	5
2	Angiotensin receptors and neuropathic pain. Pain Reports, 2021, 6, e869.	2.7	17
3	Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. International Journal of Molecular Sciences, 2021, 22, 2479.	4.1	12
4	A comprehensive time course and correlation analysis of indomethacin-induced inflammation, bile acid alterations and dysbiosis in the rat small intestine. Biochemical Pharmacology, 2021, 190, 114590.	4.4	22
5	Shedding Light on the Pharmacological Interactions between μ-Opioid Analgesics and Angiotensin Receptor Modulators: A New Option for Treating Chronic Pain. Molecules, 2021, 26, 6168.	3.8	7
6	Targeted Imaging and Therapeutic Technologies in Neuroregeneration. , 2021, , 101-120.		0
7	On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance. Molecules, 2020, 25, 2473.	3.8	16
8	Chronic treatment with rofecoxib but not ischemic preconditioning of the myocardium ameliorates early intestinal damage following cardiac ischemia/reperfusion injury in rats. Biochemical Pharmacology, 2020, 178, 114099.	4.4	6
9	Comparisons of In Vivo and In Vitro Opioid Effects of Newly Synthesized 14-Methoxycodeine-6-O-sulfate and Codeine-6-O-sulfate. Molecules, 2020, 25, 1370.	3.8	11
10	Glycine transporter inhibitors: A new avenue for managing neuropathic pain. Brain Research Bulletin, 2019, 152, 143-158.	3.0	30
11	Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat. Cells, 2019, 8, 251.	4.1	6
12	Efficacy-Based Perspective to Overcome Reduced Opioid Analgesia of Advanced Painful Diabetic Neuropathy in Rats. Frontiers in Pharmacology, 2019, 10, 347.	3.5	17
13	Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinal administration. Brain Research Bulletin, 2019, 147, 78-85.	3.0	6
14	The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats. Neurochemical Research, 2018, 43, 1250-1257.	3.3	28
15	Biochemical and pharmacological characterization of three opioid-nociceptin hybrid peptide ligands reveals substantially differing modes of their actions. Peptides, 2018, 99, 205-216.	2.4	6
16	Chronic cyclooxygenase-2 inhibition does not cause gastrointestinal damage in the rat. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-6-22.	0.0	0
17	New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology. European Journal of Pharmacology, 2017, 809, 111-121.	3.5	5
18	Analysing the effect of 11 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology, 2017, 25, 107-118.	3.9	4

#	Article	IF	CITATIONS
19	Effects of articaine on [3 H]noradrenaline release from cortical and spinal cord slices prepared from normal and streptozotocin-induced diabetic rats and compared to lidocaine. Brain Research Bulletin, 2017, 135, 157-162.	3.0	15
20	14-O-Methylmorphine: A Novel Selective Mu-Opioid Receptor Agonist with High Efficacy and Affinity. European Journal of Pharmacology, 2017, 814, 264-273.	3.5	9
21	New Morphine Analogs Produce Peripheral Antinociception within a Certain Dose Range of Their Systemic Administration. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 171-181.	2.5	23
22	A new potent analgesic agent with reduced liability to produce morphine tolerance. Brain Research Bulletin, 2015, 117, 32-38.	3.0	20